Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

February 15, 2017

Primary Completion Date

October 15, 2023

Study Completion Date

October 15, 2023

Conditions
Mild Cognitive Impairment
Interventions
DRUG

Tesamorelin

Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV

Trial Locations (4)

90033

Keck School of Medicine of the University of Southern California, Los Angeles

92103

HIV Neurobehavioral Research Program (HNRP), San Diego

92262

PalmTree, Palm Springs

94143

University of California, San Francisco, San Francisco

Sponsors
All Listed Sponsors
collaborator

University of Southern California

OTHER

collaborator

PalmTree Clinical Research Inc.

UNKNOWN

collaborator

University of California, San Francisco

OTHER

lead

University of California, San Diego

OTHER